| General information | Literature | Expression | Regulation | Mutation | Interaction |
Basic Information | |
|---|---|
Gene ID | 7021 |
Name | TFAP2B |
Synonymous | AP-2B|AP2-B;transcription factor AP-2 beta (activating enhancer binding protein 2 beta);TFAP2B;transcription factor AP-2 beta (activating enhancer binding protein 2 beta) |
Definition | AP2-beta|activating enhancer binding protein 2 beta|activating enhancer-binding protein 2-beta|transcription factor AP-2-beta |
Position | 6p12 |
Gene type | protein-coding |
Cancer type | Abstract |
| Alveolar rhabdomyosarcoma;muscular | The chromosomal translocation t(2;13), characteristic for the aggressive childhood cancer alveolar rhabdomyosarcoma (aRMS), generates the chimeric transcription factor PAX3/FKHR with a well known oncogenic role. However, the molecular mechanisms mediating essential pathophysiological functions remain poorly defined. Here, we used comparative expression profiling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific gene signatures in vivo to identify physiologically important target genes. Hereby, 51 activated genes, both novel and known, were identified. We also found repression of skeletal muscle-specificgenes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells. Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR. Hence, we developed a pathophysiologicallyrelevant transcriptional profile of PAX3/FKHR and identified a critical target gene for aRMS development. |